The treatments for COVID-19 have been limited and mostly supportive, but there has been growing interest in the use of IL-1 and IL-6 antagonists in the treatment of COVID-19 to reduce the severity of symptoms, improve the outcome of the illness, and potentially reduce the risk of death [35,42]. This evidence concerns the gene IL6 and COVID-19.